Our vision is a world where malignant cancers, or the effects of cancer treatments, no longer devastate families by imposing unacceptable suffering and mercilessly killing loved ones.

Our mission is to develop therapeutic approaches that extend and enhance cancer patients’ lives, either by reducing the malignancy of life-threatening tumors, improving the safety of current treatments, or by bringing novel solutions to make living with cancer more tolerable.

“The unique portfolio of I-O platform assets is unrivaled in the industry. It includes intracellular targeting antibodies (iTAbs), immune checkpoint inhibitors, bispecific antibodies, antibody-drug conjugates (ADCs) as well as chimeric antigen receptor (CAR)-based cellular therapies, and most recently we’ve added an oncolytic virus (Seprehvir). Each asset individually shows great promise, put together we feel they have the potential to break-through the most difficult cancer challenges”
– Dr. Henry Ji, CEO